Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02767856
Other study ID # HJW1604
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 2016
Est. completion date May 30, 2021

Study information

Verified date May 2022
Source Salus University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to answer the question: What if the Intermittent Occlusion (IO-therapy) glasses were prescribed all day (12-hours) in which the total time of treatment only took 4 weeks instead of the current treatment time (4 hours) in which it takes 12 weeks? Children aged 3- to 8-years with untreated moderate unilateral amblyopia will be enrolled and randomized into 2 groups: 1) Intense 12-hour IO-therapy Group for 4 weeks treatment; or 2) Standard 4-hour IO-therapy glasses Group for 12 weeks treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 32
Est. completion date May 30, 2021
Est. primary completion date May 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Years to 8 Years
Eligibility Inclusion Criteria: The following criteria must be met for the patient to be enrolled in the study: 1. Age 3 to < 8 years 2. Unilateral amblyopia associated with strabismus (comitant or incomitant), anisometropia, or both Criteria for strabismus: At least one of the following criteria must be met: - Heterotropia at distance and/or near fixation on examination (with or without spectacles) - History of strabismus surgery - Documented history of strabismus which is no longer present (which in the judgment of the investigator could have caused amblyopia) Criteria for anisometropia: At least one of the following criteria must be met: - >0.50 D difference between eyes in spherical equivalent - >0.50 D difference between eyes in astigmatism in any meridian 3. Amblyopic eye has no myopia (> -0.25 D spherical equivalent). 4. Visual acuity, measured in each eye without cycloplegia within 7 days prior to enrollment using the ATS single-surround HOTV letter protocol as follows: - Visual acuity in the amblyopic eye between 20/40 and 20/80 inclusive - Visual acuity in the sound eye 20/32 or better - Inter-eye acuity difference = 2 logMAR lines (i.e., amblyopic eye acuity at least 2 lines worse than sound eye acuity) 5. No previous amblyopia treatment within 6 months. 6. Spectacle correction (if applicable) for measurement of enrollment visual acuity must meet the following criteria and be based on a cycloplegic refraction within 6 months: - Requirements for spectacle correction: - For patients meeting criteria for only strabismus - Hypermetropia if corrected must not be undercorrected by more than +1.50 D spherical equivalent, and the reduction in plus sphere must be symmetric in the two eyes. Otherwise, spectacle correction is at investigator discretion. - For patients meeting criteria for anisometropia or combined-mechanism - Spherical equivalent must be within 0.50 D of fully correcting the anisometropia - Hypermetropia must not be undercorrected by more than +1.50 D spherical equivalent, and reduction in plus must be symmetric in the two eyes - Cylinder power in both eyes must be within 0.50 D of fully correcting the astigmatism - Cylinder axis in the spectacle lenses in both eyes must be within 6 degrees of the axis of the cycloplegic refraction Spectacles meeting above criteria must be worn either: - for 4 weeks immediately prior to enrollment, or - until visual acuity in amblyopic eye is stable (defined as two consecutive visual acuity measurements at least 4 weeks apart with no improvement of one line or more) - An acuity measurement done any of the following ways may be considered the first of two consecutive measurements: - in current glasses, - in trial frames with full correction of hypermetropia with cycloplegia, or - in new glasses. 7. Wearing optimal spectacle correction for a minimum of 4 weeks at the time of enrollment. 8. Ocular examination within 6 months prior to enrollment. 9. Gestational age > 34 weeks and birth weight > 1500 grams 10. Parent willing to accept randomization 11. Parent willing to be contacted and has access to phone 12. Parent does not anticipate relocation outside area within study period. Exclusion Criteria: 1. Amblyopic eye has myopia worse than -3.00 D spherical equivalent. 2. Prior intraocular or refractive surgery 3. Ocular pathologies that impact vision 4. Cognitive impairment that prohibits accurate data collection

Study Design


Related Conditions & MeSH terms


Intervention

Device:
IO-therapy Glasses


Locations

Country Name City State
United States Salus University Elkins Park Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Salus University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Acuity Improvement visual acuity difference between the primary outcome measure and baseline in the amblyopic eye; visual acuity was measured with ATS- HOTV method 4 weeks for the Intense Group and 12 weeks for the Standard Group
Secondary Stereoacuity Test Stereoacuity in arcsec was converted to log scale. so log10(stereo) will be reported.
The higher value indicates a poorer binocular visual function.
4 weeks for the Intense Group and 12 weeks for the Standard Group
Secondary Objective Total Treatment Hours Objective total treatment hours at the primary outcome visit measured with a microsensor 4 weeks for the Intense Group and 12 weeks for the Standard Group
Secondary Objective Adherence objective adherence measured with a microsensor to the treatment regimen 4 weeks for the Intense Group and 12 weeks for the Standard Group
See also
  Status Clinical Trial Phase
Recruiting NCT04238065 - A Clinical Trial of Caterna Virtual Reality Facilitating Treatment in Children With Amblyopia N/A
Completed NCT04432181 - Comparison of Deviation Types Among Astigmatic Children With Or Without Amblyopia
Completed NCT02458846 - Efficacy of Visual Screening in Ontario N/A
Completed NCT01190813 - Levodopa for the Treatment of Residual Amblyopia Phase 3
Completed NCT01109459 - Multimodal Physician Intervention to Detect Amblyopia N/A
Completed NCT04313257 - Monocular Action Video Game Treatment of Amblyopia N/A
Completed NCT04315649 - Effect of 3D Movie Viewing on Stereopsis in Strabismus and / or Anisometropic Amblyops N/A
Completed NCT05223153 - OCT-A and Amblyopia
Recruiting NCT05522972 - Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games N/A
Completed NCT01430247 - Vision Screening for the Detection of Amblyopia N/A
Completed NCT02200211 - Study of Binocular Computer Activities for Treatment of Amblyopia N/A
Recruiting NCT06429280 - Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
Withdrawn NCT04959422 - Assuring Ophthalmologic Follow up N/A
Active, not recruiting NCT05612568 - 5 Years of Eye Screening for ARF in Children Aged <3 Years in Flanders
Recruiting NCT03655912 - Binocular Visual Therapy and Video Games for Amblyopia Treatment. N/A
Recruiting NCT06150391 - Evaluation of Amblyopia Protocols Using a Dichoptic Gabor Videogame Program N/A
Completed NCT03754153 - Binocularly Balanced Viewing Study N/A
Withdrawn NCT02594358 - Caffeine in Amblyopia Study Phase 1/Phase 2
Terminated NCT02246556 - Dichoptic Virtual Reality Therapy for Amblyopia in Adults Phase 1
Completed NCT02003235 - Assessment of Device for Treatment of Amblyopia N/A